NEW YORK, Aug. 6, 2012 — (PRNewswire) — Reportlinker.com announces that a new market research report is available in its catalogue:

Medical Imaging Markets: Contrast Agents

http://www.reportlinker.com/p0158569/Medical-Imaging-Markets-Contrast-Agents.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging

Today's capabilities in clinical diagnostic radiology have been made possible by advances not only in diagnostic systems, but also by the contrast media and radiopharmaceuticals that make it possible to see, in great detail, the body's internal structures, organs and tissue that would not otherwise be clearly seen. Although bones are readily apparent on radiographic images, other organs and tissues are not. These imaging agents may be used during a medical imaging procedure to highlight specific parts of the body and make them easier to visualize. The application and versatility of medical imaging modalities are continuing to grow in significance as the population ages and healthcare costs rise. Examinations that can facilitate earlier disease diagnosis and the most appropriate treatment are in order. This bodes well for contrast media markets.

Generally, the market for contrast agents and radiopharmaceuticals is expected to sustain decent growth in the next few years, with much of that growth coming from the MRI, ultrasound and nuclear medicine modalities. While equipment manufacturers may have experienced a slump in sales due to the recent recession, there is still a need for these agents,as well as for radiopharmaceuticals, to help image, track and diagnose disease, especially in the elderly. Even though hospitals and clinics may have slowed their equipment purchases because of the need to contain costs, procedures run on installed systems still require the use of contrast agents and radiopharmaceuticals.

This comprehensive study of the world market for contrast agents builds on the previous modality-focused reports of Kalorama's medical imaging market reports. Coverage includes:

• World and regional revenue forecasts for contrast agents and radiopharmaceuticals by modality through 2016. (X-Ray, CT, Ultrasound, MRI, PET, SPECT)

• Market share of the major contrast agent supplers

• Procedure volumes by modality and region

• Estimates of the portion of procedures in each modality using contrast enhancement

• Contrast-enhancement products in development

The report also discusses technical developments and emerging application trends such as therapeutic monitoring, whole body screening, and guided therapeutic interventions, and how contrast agents are helping to expand imaging's role in basic research and drug discovery/development. Specific advances in contrast agent-enabled diagnostics for mammography, Alzheimer's, and other indications are also reviewed.

CHAPTER ONE: Executive Summary

• Image Enhancament Overview

• X-Ray and CT

• Ultrasound

• MRI

• Radiopharmaceuticals

• World Market Summary

• Volume Growth

• New Diagnostics

• Toxicity Issues

• Generic Competition

• World Market Growth Analysis

• Methodology

CHAPTER TWO: Introduction

• Agents for the Early Detection of Disease

• Two Functions

• Adding Value

• Key Clinical Markets

• X-Ray and CT

• Ultrasound

• Updated Warning on Microbubbles

• Microbubble Composition

• Targeted and Untargeted

• MRI

• Novel Agents

• Nuclear Medicine

• Diagnosing Functionality

• Sourcing Issues Updated

• PET

• New Applications

• SPECT

• Gamma Cameras

• Risks

• Ionic and Non-Ionic Contrast

• Issues

• Utilization Rate

• Technical Challenges

• Tracking Contrast Media

• Contrast Modality Combinations

• Emerging Applications

• Atherosclerosis

• Nanotechnology

CHAPTER THREE: Market Developments

• Market Developments

• FDA Approves Amyvid

• Bayer HealthCare Business Integration

• Bayer Receives Gadavist Approval

• Agfa's Generic Push

• Agfa's Generic Push

• Improving Magnetic Resonance Visualization

• Nanoparticle Contrast

• Tracking Stem Cells

CHAPTER FOUR: Markets

• Market Drivers

• Withstanding the Recession

• Combination Imaging and Disease Management

• Opportunities from Increasing Specificity

• Aging Population

• Utilization

• Procedures

• Outlook for Contrast Media

• Market Forecast

• X-Ray and CT

• Ultrasound

• MRI

• Outlook for Molecular Imaging Agents

• Market Forecast

CHAPTER FIVE: Corporate Profiles

• Acusphere Inc..

• Alseres Pharmaceuticals, Inc.

• Amag Pharmaceuticals Inc

• Aposense Ltd

• ART Advanced Research Technologies Inc.

• Avid Radiopharmaceuticals Inc

• Bayer HealthCare

• Bracco SpA

• Cardinal Health

• Cell>Point

• Covidien plc

• Daiichi Pharmaceutucal Co. Ltd

• Draximage

• Endocyte Inc

• Eusa Pharma

• FluoroPharma Medical Inc

• GE Healthcare

• Guerbet Group

• Hovione Farmaciencia SA

• Immunomedics Inc

• Insight Agents

• Kereos Inc

• King Pharmaceuticals

• Lantheus Medical Imaging

• Luna Nanoworks

• Macrocyclics

• MDS Nordion

• Molecular Insight Pharmaceuticals, Inc

• Nanoscan Imaginf LLC

• Palatin Technologies Inc

• Pharmacyclics

• Spago Imaging AB

• Targeson Inc

• Taejoon Pharmaceutical Co. Ltd

• VisEn Medical

• Zim Laboratories India Ltd

List of Exhibits

CHAPTER ONE: Executive Summary

• Executive SummaryExhibit 1:World Market for X-Ray Medical Contrast Media, 2011-2015

• Exhibit 2:World Market for CT Medical Contrast Media, 2011-2015

• Exhibit 3:World Market for Ultrasound Medical Contrast Media, 2011-2015

• Exhibit 4:World Market for MRI Medical Contrast Media, 2011-2015

• Exhibit 5:World Market for PET Radiopharmaceuticals, 2011-2015

• Exhibit 6:World Market for SPECT Radiopharmaceuticals, 2011-2015

1 | 2  Next Page »